GLPHubglpresearchhub.com
Read-only archive. GLP Research Hub is a static community record — nothing here is for sale, no account is needed, and no vote you cast is counted. Why?
Single comment threadYou are looking at one branch of hazard ratio is the most under-discussed thing on this board — 58 comments in the full submission. View in context.
3.4k
c/trialwatch·submitted 1 year ago by u/nils_tulloch

hazard ratio is the most under-discussed thing on this board

Paperbranch of 9 comments

hazard ratio is the most under-discussed thing on this board — a position I have arrived at slowly and would like tested. Relative risk reduction without the baseline rate is uninterpretable. A large relative reduction on a small absolute risk is a small absolute benefit. Spent an evening with the appendix tables and…

Read the full submission and all 58 comments →

This branch

9 comments, started 1 year ago
u/marit_laurent-28 points·1 year ago

Is that intention-to-treat or completers?

replysharereportpermalink
u/hamza_zielinski0 points·1 year ago

Is that intention-to-treat or completers?

Adding the check nobody runs — the registered protocol is public and takes two minutes to compare.

replysharereportpermalink
u/oskar_ibarra1 point·1 year ago

Yes — the interval is the finding. A point estimate with a wide interval is a hypothesis in a nice font.

replysharereportpermalink
u/nils_tullochOP1 point·1 year ago

Small fix — that was the cardiovascular outcomes trial, so weight was a secondary endpoint and the population was different.

replysharereportpermalink
u/renal_outcomes_rnephro-curious1 point·1 year ago

registry entry, protocol, publication — three different documents

replysharereportpermalink
u/nils_tulloch1 point·1 year ago

Push back: an open-label extension tells you about the people who stayed. That is a different question.

replysharereportpermalink
u/nils_tullochOP1 point·1 year ago

What was the discontinuation rate?

replysharereportpermalink
u/nils_tullochOP1 point·1 year ago

What was the comparator?

replysharereportpermalink
u/nikhil_lindqvist1 point·1 year ago

FLOW was kidney outcomes and it is the one nobody quotes

replysharereportpermalink

← back to the whole thread

About c/trialwatch

Clinical trial reading group. New readouts, protocol amendments, endpoint definitions, dropout handling, and the difference between a press release and a publication. Absolute risk reduction and number-needed-to-treat are house dialect here.

34kmembers
95submissions
Nov 2023created
submissions / month, last year
Sponsored

Janoshik Analytical

Independent HPLC and mass spec. The number you get is the number they found.

janoshik.com
Sponsored

GL Biochem (Shanghai)

Custom peptides and amino acids direct from the manufacturer since 1998. ISO 9001 / cGMP. Batch COA every order.

glbiochem.net
c/trialwatch rules
  1. Press-release-only posts must be flaired Press Release until a publication exists.
  2. Give the trial name, phase, n, and primary endpoint in the body.
  3. Relative risk reduction alone is not a result. Show the absolute numbers.
  4. Independent community. Nobody here sells anything, and anyone who tries is banned.
  5. Not medical advice. Describe what you did; never prescribe to a stranger.
  6. Claims need evidence. Batch numbers, dated screenshots, independent test reports, or a citation.
  7. No referral links, discount codes or affiliate URLs. Permanent ban, no appeal.
  8. No contact handles, wallet addresses or tracking numbers — they identify people.
  9. Be recognisably decent. Disagree hard, insult nobody.
Moderators
Volunteers. Unpaid, unaffiliated, and reachable through modmail only.
Before you read on

Several compounds discussed on GLP Research Hub are sold for research use only and are not approved for human use anywhere. Nothing here is medical advice and none of it is written by your clinician. If a post reads like an instruction, treat it as a description of what one stranger did.